Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Holmström F, Chen M, Balasiddaiah A, Sällberg M, Ahlén G, Frelin L.

Sci Rep. 2016 May 4;6:24991. doi: 10.1038/srep24991.

2.

Comparative Immunogenicity in Rabbits of the Polypeptides Encoded by the 5' Terminus of Hepatitis C Virus RNA.

Sominskaya I, Jansons J, Dovbenko A, Petrakova N, Lieknina I, Mihailova M, Latyshev O, Eliseeva O, Stahovska I, Akopjana I, Petrovskis I, Isaguliants M.

J Immunol Res. 2015;2015:762426. doi: 10.1155/2015/762426. Epub 2015 Nov 2.

3.

Progress in the development of vaccines for hepatitis C virus infection.

Ghasemi F, Rostami S, Meshkat Z.

World J Gastroenterol. 2015 Nov 14;21(42):11984-2002. doi: 10.3748/wjg.v21.i42.11984. Review.

4.

Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.

Lepiller Q, Soulier E, Li Q, Lambotin M, Barths J, Fuchs D, Stoll-Keller F, Liang TJ, Barth H.

J Innate Immun. 2015;7(5):530-44. doi: 10.1159/000375161. Epub 2015 Mar 19.

5.

Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Verstrepen BE, Boonstra A, Koopman G.

World J Hepatol. 2015 Jan 27;7(1):53-69. doi: 10.4254/wjh.v7.i1.53. Review.

6.

Influence of HIV and HCV on T cell antigen presentation and challenges in the development of vaccines.

John M, Gaudieri S.

Front Microbiol. 2014 Oct 13;5:514. doi: 10.3389/fmicb.2014.00514. eCollection 2014. Review.

7.

Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G.

World J Gastroenterol. 2014 Aug 7;20(29):9633-52. doi: 10.3748/wjg.v20.i29.9633. Review.

8.

CD8(+) T-Cell Responses in Acute Hepatitis C Virus Infection.

Sung PS, Racanelli V, Shin EC.

Front Immunol. 2014 Jun 6;5:266. doi: 10.3389/fimmu.2014.00266. eCollection 2014. Review.

9.

Will there be a vaccine to prevent HCV infection?

Honegger JR, Zhou Y, Walker CM.

Semin Liver Dis. 2014 Feb;34(1):79-88. doi: 10.1055/s-0034-1371081. Epub 2014 Apr 29. Review.

10.

Strong vaccine-induced CD8 T-cell responses have cytolytic function in a chimpanzee clearing HCV infection.

Verstrepen BE, Verschoor EJ, Fagrouch ZC, Mooij P, de Groot NG, Bontrop RE, Bogers WM, Heeney JL, Koopman G.

PLoS One. 2014 Apr 16;9(4):e95103. doi: 10.1371/journal.pone.0095103. eCollection 2014.

11.

Evolution to a chronic disease niche correlates with increased sensitivity to tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae.

Huston WM, Barker CJ, Chacko A, Timms P.

J Bacteriol. 2014 Jun;196(11):1915-24. doi: 10.1128/JB.01476-14. Epub 2014 Mar 28. Review.

12.

Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade.

Ma CJ, Ren JP, Li GY, Wu XY, Brockstedt DG, Lauer P, Moorman JP, Yao ZQ.

PLoS One. 2014 Jan 31;9(1):e87821. doi: 10.1371/journal.pone.0087821. eCollection 2014.

13.

Changes in immune cell populations in the periphery and liver of GBV-B-infected and convalescent tamarins (Saguinus labiatus).

Hood SP, Mee ET, Perkins H, Bowen O, Dale JM, Almond NM, Karayiannis P, Bright H, Berry NJ, Rose NJ.

Virus Res. 2014 Jan 22;179:93-101. doi: 10.1016/j.virusres.2013.11.006. Epub 2013 Nov 15.

14.

Emerging concepts in immunity to hepatitis C virus infection.

Rosen HR.

J Clin Invest. 2013 Oct;123(10):4121-30. doi: 10.1172/JCI67714. Epub 2013 Oct 1. Review.

15.

Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).

Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, Ahmed R, Walker CM.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15001-6. doi: 10.1073/pnas.1312772110. Epub 2013 Aug 26.

16.

Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M.

Mol Ther. 2013 Sep;21(9):1796-805. doi: 10.1038/mt.2013.119. Epub 2013 Jun 11.

17.

Ever closer to a prophylactic vaccine for HCV.

Swadling L, Klenerman P, Barnes E.

Expert Opin Biol Ther. 2013 Aug;13(8):1109-24. doi: 10.1517/14712598.2013.791277. Epub 2013 May 7. Review.

18.

The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection.

Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, de Re V, Feinstone SM, Rice CM, Rehermann B.

J Virol. 2013 Apr;87(8):4772-7. doi: 10.1128/JVI.03122-12. Epub 2013 Feb 6.

19.

Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.

Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S, Frenzke ME, Forest A, Whidby J, Marcotrigiano J, Rice CM, Cattaneo R.

J Virol. 2012 Nov;86(21):11558-66. doi: 10.1128/JVI.01776-12. Epub 2012 Aug 15.

20.

Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.

Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, Folgori A, Rehermann B.

Gastroenterology. 2012 Oct;143(4):1048-60.e4. doi: 10.1053/j.gastro.2012.06.005. Epub 2012 Jun 13.

Supplemental Content

Support Center